Biogen C.E.O. to Step Down Following Launch of Alzheimer’s Drug, Aduhelm

The drug company will effectively give up on marketing Aduhelm, which comes with unproven benefit and serious safety risks.

from NYT > Health https://ift.tt/tAxv3NE
via health&fitness